A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis

The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Paul C. Langley
Formato:	article
Lenguaje:	EN
Publicado:	University of Minnesota Libraries Publishing 2021
Materias:	ICER, myasthenia gravis claims, pseudoscience, value claims, N-QOL Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/d7b83b07b71f43c58222455a5e18945b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d7b83b07b71f43c58222455a5e18945b
record_format	dspace
spelling	oai:doaj.org-article:d7b83b07b71f43c58222455a5e18945b2021-12-05T18:44:04ZA Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis10.24926/iip.v12i4.43902155-0417https://doaj.org/article/d7b83b07b71f43c58222455a5e18945b2021-10-01T00:00:00Zhttps://pubs.lib.umn.edu/index.php/innovations/article/view/4390https://doaj.org/toc/2155-0417 The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping ordinal EQ-5D-5L preferences from the ordinal Quantitative Myasthenia Gravis (QMG) score. A second aspect of this commentary is to propose standards that should be set for the creation and evaluation of value claims in health technology assessment, in particular need fulfillment quality of life (QoL), that meet the demarcation test to distinguish science from non-science. The result is that the present ICER pricing claims for eculizumab and efgartigimod in myasthenia gravis should not be applied without consideration of more relevant evidence. Paul C. LangleyUniversity of Minnesota Libraries PublishingarticleICER, myasthenia gravis claims, pseudoscience, value claims, N-QOL Pharmacy and materia medicaRS1-441ENINNOVATIONS in Pharmacy, Vol 12, Iss 4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ICER, myasthenia gravis claims, pseudoscience, value claims, N-QOL Pharmacy and materia medica RS1-441
spellingShingle	ICER, myasthenia gravis claims, pseudoscience, value claims, N-QOL Pharmacy and materia medica RS1-441 Paul C. Langley A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
description	The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping ordinal EQ-5D-5L preferences from the ordinal Quantitative Myasthenia Gravis (QMG) score. A second aspect of this commentary is to propose standards that should be set for the creation and evaluation of value claims in health technology assessment, in particular need fulfillment quality of life (QoL), that meet the demarcation test to distinguish science from non-science. The result is that the present ICER pricing claims for eculizumab and efgartigimod in myasthenia gravis should not be applied without consideration of more relevant evidence.
format	article
author	Paul C. Langley
author_facet	Paul C. Langley
author_sort	Paul C. Langley
title	A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
title_short	A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
title_full	A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
title_fullStr	A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
title_full_unstemmed	A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
title_sort	critical examination for the pricing of eculizumab and efgartigimod in myasthenia gravis
publisher	University of Minnesota Libraries Publishing
publishDate	2021
url	https://doaj.org/article/d7b83b07b71f43c58222455a5e18945b
work_keys_str_mv	AT paulclangley acriticalexaminationforthepricingofeculizumabandefgartigimodinmyastheniagravis AT paulclangley criticalexaminationforthepricingofeculizumabandefgartigimodinmyastheniagravis
_version_	1718371092780810240

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis

Ejemplares similares